Recent discussions on X about SELLAS Life Sciences Group (SLS) have centered around the company's upcoming R&D Day and promising updates on their clinical trials. Posts highlight excitement over new data for acute myeloid leukemia (AML) treatments, with some noting a significant after-hours stock surge of over 40%. There's also mention of a recent capital raise of $23.6 million, which many see as a bolster to the company's financial position for late-stage trials.
The buzz on X also includes speculation about potential partnerships or buyouts, fueled by reports of strategic advisory involvement, though nothing is confirmed. Some users are pointing to preclinical data presented at a recent medical congress as a sign of strong future prospects. The conversation remains dynamic, with a focus on whether these catalysts could drive further momentum for the biotech stock.
Note: This discussion summary was generated from an AI condensation of post data.
SELLAS Life Sciences Group Insider Trading Activity
SELLAS Life Sciences Group insiders have traded $SLS stock on the open market 3 times in the past 6 months. Of those trades, 3 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $SLS stock by insiders over the last 6 months:
- KATHERINE BACH KALIN purchased 20,000 shares for an estimated $36,000
- JANE WASMAN purchased 20,000 shares for an estimated $33,800
- NOSTRAND ROBERT L VAN purchased 10,000 shares for an estimated $14,800
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
SELLAS Life Sciences Group Hedge Fund Activity
We have seen 62 institutional investors add shares of SELLAS Life Sciences Group stock to their portfolio, and 16 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANSON FUNDS MANAGEMENT LP removed 7,304,095 shares (-96.4%) from their portfolio in Q2 2025, for an estimated $15,995,968
- BLACKROCK, INC. added 4,051,813 shares (+752.5%) to their portfolio in Q2 2025, for an estimated $8,873,470
- VANGUARD GROUP INC added 3,815,481 shares (+134.4%) to their portfolio in Q2 2025, for an estimated $8,355,903
- MARSHALL WACE, LLP added 2,704,007 shares (+23550.0%) to their portfolio in Q2 2025, for an estimated $5,921,775
- GEODE CAPITAL MANAGEMENT, LLC added 1,379,988 shares (+168.2%) to their portfolio in Q2 2025, for an estimated $3,022,173
- MILLENNIUM MANAGEMENT LLC added 1,127,225 shares (+inf%) to their portfolio in Q2 2025, for an estimated $2,468,622
- MORGAN STANLEY added 1,018,028 shares (+1532.0%) to their portfolio in Q2 2025, for an estimated $2,229,481
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
SELLAS Life Sciences Group Analyst Ratings
Wall Street analysts have issued reports on $SLS in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/16/2025
To track analyst ratings and price targets for SELLAS Life Sciences Group, check out Quiver Quantitative's $SLS forecast page.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
